Globus Medical, Inc. Class A Common Stock (GMED)
84.28
-3.10 (-3.55%)
Globus Medical Inc is a medical device company that specializes in the development and commercialization of innovative products for spine surgery
The company focuses on creating solutions that enhance surgical outcomes and improve patient recovery through advanced technologies, including surgical implants, instruments, and robotics. With a robust portfolio, Globus Medical aims to address various spinal conditions and assist healthcare professionals in providing effective treatment options, ultimately striving to elevate the standard of care in spine surgery.
Previous Close | 87.38 |
---|---|
Open | 86.75 |
Bid | 84.00 |
Ask | 86.50 |
Day's Range | 84.23 - 87.04 |
52 Week Range | 49.33 - 94.93 |
Volume | 1,105,298 |
Market Cap | 11.48B |
PE Ratio (TTM) | 129.66 |
EPS (TTM) | 0.7 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 1,314,936 |
News & Press Releases
![](https://cdn.benzinga.com/files/images/story/2023/valuestock_image_1.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · February 10, 2025
![](https://www.chartmill.com/images/uploads/Affordable_Growth_500_264px_webp_add6a3aa59.webp)
Based on Fundamental Analysis it can be said that NYSE:GMED is a growth stock which is not overvalued.
Via Chartmill · February 7, 2025
![](https://ml.globenewswire.com/media/46f81a86-b794-42b0-bf72-63447eb13f53/small/gmlogo-2024-rgb-high-png.png)
AUDUBON, Pa. and REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical (NYSEGMED), a leading musculoskeletal solutions company, and Nevro Corp. NYSE: NVRONYSENVRO)
By Globus Medical · Via GlobeNewswire · February 6, 2025
![](https://www.chartmill.com/images/uploads/HGM_Breakout_19d1a7df53.webp)
A fundamental and technical analysis of (NYSEGMED): Exploring GLOBUS MEDICAL INC - A NYSE:GMEDNYSEGMED)
Via Chartmill · January 29, 2025
![](https://www.chartmill.com/images/uploads/HGM_Breakout_19d1a7df53.webp)
Delving into GLOBUS MEDICAL INC - A (NYSEGMED)'s high Growth Prospects.
Via Chartmill · December 31, 2024
![](https://ml.globenewswire.com/media/46f81a86-b794-42b0-bf72-63447eb13f53/small/gmlogo-2024-rgb-high-png.png)
AUDUBON, Pa., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSEGMED), a leading musculoskeletal solutions company, will announce its financial results for the fourth quarter and full-year ended December 31, 2024 after the market close on Thursday, February 20, 2025. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com.
By Globus Medical · Via GlobeNewswire · January 30, 2025
![](https://www.investors.com/wp-content/uploads/2017/05/IRU77.jpg)
Reflecting its strong growth, on Monday the Relative Strength (RS) Rating for Stryker stock got an upgrade from 70 to 74.
Via Investor's Business Daily · January 13, 2025
![](https://ml.globenewswire.com/media/46f81a86-b794-42b0-bf72-63447eb13f53/small/gmlogo-2024-rgb-high-png.png)
AUDUBON, Pa., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSEGMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales results for the fourth quarter and full year ending December 31, 2024. The company anticipates fourth quarter 2024 sales of approximately $657.0 million, an increase of 6.6 percent over the fourth quarter 2023 on an as-reported basis. Full year 2024 sales are expected to be approximately $2.52 billion, an increase of 60.6 percent over the prior year on an as-reported basis.
By Globus Medical · Via GlobeNewswire · January 8, 2025
![](https://www.investors.com/wp-content/uploads/2019/10/stock-sleep-01-shutter.jpg)
Inspire Medical, which makes innovative apnea relief devices, hit a key performance benchmark as its Relative Strength Rating jumped to 81.
Via Investor's Business Daily · January 8, 2025
![](https://www.chartmill.com/images/uploads/HGM_Breakout_19d1a7df53.webp)
Unlocking the high Growth Potential of GLOBUS MEDICAL INC - A (NYSEGMED).
Via Chartmill · December 10, 2024
![](https://www.investors.com/wp-content/uploads/2017/05/IRU1.jpg)
On Tuesday, Novocure stock got a positive adjustment to its Relative Strength (RS) Rating to 96, up from 73.
Via Investor's Business Daily · December 3, 2024
![](https://mms.businesswire.com/media/20250108999131/en/765953/22/Close_Up_Logo_HD_Blue.jpg)
The Law Offices of Frank R. Cruz continues its investigation on behalf of Globus Medical, Inc. (“Globus Medical” or the “Company”) (NYSEGMED) investors concerning the Company and its officers’ possible violations of federal securities laws.
By The Law Offices of Frank R. Cruz · Via Business Wire · January 8, 2025
![](https://www.investors.com/wp-content/uploads/2017/05/IRU4.jpg)
Lantheus Holdings sees its Relative Strength Rating reach the 80-plus level.
Via Investor's Business Daily · January 7, 2025
![](https://www.investors.com/wp-content/uploads/2017/05/IRU6.jpg)
On Wednesday, Inari Medical stock received an upgrade to its Relative Strength (RS) Rating, from 65 to 72.
Via Investor's Business Daily · December 11, 2024
![](https://cdn.benzinga.com/files/images/story/2024/12/02/Modern-Hospital-And-Communication-Networ.jpeg?width=1200&height=800&fit=crop)
Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges.
Via Benzinga · December 2, 2024
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_4.png?width=1200&height=800&fit=crop)
Via Benzinga · December 2, 2024
![](https://ml.globenewswire.com/media/46f81a86-b794-42b0-bf72-63447eb13f53/small/gmlogo-2024-rgb-high-png.png)
AUDUBON, Pa., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSEGMED), a leading musculoskeletal solutions company, today announced the commercial launch of the ExcelsiusHub™ navigation system. ExcelsiusHub™ joins the expansive ecosystem of Excelsius™ technologies and is designed to elevate the standard for freehand navigation.
By Globus Medical · Via GlobeNewswire · November 22, 2024
![](https://www.chartmill.com/images/uploads/Affordable_Growth_500_264px_webp_add6a3aa59.webp)
GLOBUS MEDICAL INC - A (NYSEGMED) stands out as a growth opportunity that won't break the bank.
Via Chartmill · November 7, 2024
![](https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg)
GMED earnings call for the period ending September 30, 2024.
Via The Motley Fool · November 5, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · November 6, 2024